Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

905 results about "A lipoprotein" patented technology

Difunctional cavings oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity

The invention discloses a bifunctional cavings oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity and application of the bifunctional cavings oligopeptide GK-8. The amino acid sequence of the cavings oligopeptide is Gly-Leu-Ser-Phe-Asp-Phe-Tyr-Lys (GLSFDFYK, called GK-8 for short). Experiments find that the GK-8 has the effects of preventing and treating the metabolic syndrome of the mice, specifically, the GK-8 can obviously reduce the body weight of the mice, improve fatty degeneration and obviously reduce insulin resistance of the mice; the levels of triglyceride TG, total cholesterol TC and low-density lipoprotein LDL-C in mouse serum are obviously reduced, and the level of high-density lipoprotein HDL-C is increased; meanwhile, it is found that the GK-8 significantly activates the immunoregulation ability of an immunosuppressive mouse induced by cyclophosphamide, for example, the weight, thymus index and spleen index of the immunosuppressive mouse are recovered; the multiplication capacity of T lymphocytes and B lymphocytes of the spleen of the mouse, the killing activity of NK cells and the like are enhanced. The bran oligopeptide GK-8 is expected to be further researched and developed into related medicine products for preventing and treating the metabolic syndrome and improving the immunity, and the bran oligopeptide GK-8 has a wide application prospect.
Owner:SHANXI UNIV

Methods of identifying a subject for treatment with antibodies against oxidized low density lipoprotein using pericoronary fat attenuation index

The disclosure provides methods of identifying a subject for treatment with an anti-ox-LDL antibody. The disclosure also provides methods of treating a subject with an anti-ox-LDL antibody, wherein the subject has been identified to as a candidate for anti-oxLDL antibody therapy. The methods described herein use computed tomography to identify subjects who are a candidate for anti-oxLDL antibody therapy, wherein a subject may be determined to be a candidate for anti-oxLDL antibody therapy by evaluating their fat attenuation index (FAI), perivascular adipose tissue (PVAT), pericoronary adipose tissue, FAI score, FAI percentile, or CaRi-Heart® Risk score.
Owner:ABCENTRA LLC

Preparation method of cereal fermentation broth metaplasm and application of cereal fermentation broth metaplasm in improvement of systemic chronic inflammation and reduction of cholesterol and low-density lipoprotein

The invention provides a preparation method of cereal fermentation broth postbiotics and application of the cereal fermentation broth postbiotics in improvement of systemic chronic inflammation and reduction of cholesterol and low-density lipoprotein, and belongs to the technical field of fermentation engineering. The invention provides a preparation method of cereal fermentation broth metabiotics, which is characterized in that mixed cereals are used as raw materials, anaerobic fermentation is carried out by using compound enzymes and various bacteria, and polysaccharides and proteins in the cereal raw materials can be quickly converted into functional small molecular substances, such as polypeptides, total phenols and total flavonoids. The cereal fermentation broth metagen can inhibit secretion of a macrophage proinflammatory medium, inhibit generation of inflammatory factors of liver, heart and intestinal tissues, and improve activation of adipose tissue macrophages related to body inflammation. After the cereal fermentation liquor is subjected to post-biogen treatment, glucose and lipid metabolism disorder can be effectively improved, liver function damage can be relieved, and the intestinal barrier function can be effectively improved.
Owner:TALENT VERTICAL & HORIZONTAL (TIANJIN) NUTRITION TECH DEV CO LTD +1

Recombinant vector for expressing LPL, recombinant bacterium and LPL production method

The invention provides a recombinant vector for expressing LPL, a recombinant bacterium and an LPL production method, and belongs to the technical field of gene engineering. The invention provides a recombinant expression vector of Pseudomonas aeruginosa lipoprotein lipase LPL, wherein an LPL coding gene is derived from Pseudomonas aeruginosa. The recombinant expression vector is introduced into a pseudomonas aeruginosa PAO1 cell, an expression strain is successfully constructed, the expression quantity of target protein is improved, efficient expression of LPL in PAO1 is achieved, and the produced LPL is high in enzyme activity and wider in application range.
Owner:JIAPU TIANCHENG (SHANGHAI) BIOTECHNOLOGY CO LTD

Rnai agents for dual inhibition of expression of apolipoprotein c-iii (APOC3) and proprotein convertase subtilisin kexin 9 (PCSK9), compositions thereof, and methods of use

PCT designated stageWO2025184301A1Organic active ingredientsSpecial deliveryDiseaseProprotein Convertase Subtilisin/Kexin 9
Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and / or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.
Owner:ARROWHEAD PHARMACEUTICALS INC

Sirna molecule for inhibiting PCSK9 expression and use thereof

Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.
Owner:HANGZHOU DINOVATE BIOTECH CO LTD

Infection diagnosis and characterization using diffusion and relaxation edited proton NMR spectroscopy

1H-NMR spectroscopic molecular markers are provided for identifying medical risk signatures such as SARS-CoV-2 infection, acute inflammation, or a cardiovascular risk condition. The markers use a combination of NMR intensity signals, including a Glyc signal from at least one N-acetyl (—NCOCH3) glycoprotein and an SPC signal from a choline head group (+N—(CH3)3) of a supramolecular phospholipids cluster (SPC) present in HDL and LDL lipoprotein subfractions. The Glyc signal is in a chemical shift region from #=2.00 ppm to #=2.20 ppm, and includes signals GlycA (2.00 ppm to 2.09 ppm) and GlycB (2.09 ppm to 2.2 ppm). The SPC signal is in a chemical shift region from #=3.20 ppm to #=3.30 ppm, and includes signals SPC1 (3.2 ppm to 3.235) ppm, SPC2 (3.235 ppm to 3.26 ppm), and SPC3 (3.26 ppm to 3.3 ppm). A system for identifying the markers is also provided.
Owner:BRUKER BIOSPIN MRI GMBH +1

Oxidized low-density lipoprotein detection method and equipment based on magnetic microsphere luminescence

The invention discloses an oxidized low-density lipoprotein detection method and oxidized low-density lipoprotein detection equipment based on magnetic microsphere luminescence, and the method comprises the following steps: carrying out alkaline phosphatase labeling on an oxidized low-density lipoprotein antibody by using the oxidized low-density lipoprotein antibody, carrying out mixed reaction on the other antibody and modified carboxyl / toluenesulfonyl microspheres, and carrying out separation and purification to obtain a target product, a chemiluminescence immunoassay system is constructed, and oxidized low-density lipoprotein antigens in a sample, enzyme-labeled antibodies and labeled magnetic beads form a'magnetic bead-antibody-antigen-enzyme-labeled antibody 'compound. Then, through a two-step cleaning process, an optical signal value RLU is generated under the action of a light-emitting substrate APS-5, and finally, the optical signal value is amplified by a photomultiplier tube PMT in light-emitting equipment. According to the scheme, the specificity can be improved from the sample capturing end, and the sensitivity can be enhanced at the signal processing end.
Owner:XIAN GOLDMAG NANOBIOTECH

Method and equipment for detecting oxidized low-density lipoprotein based on immunoturbidimetry

The invention discloses a method and equipment for detecting oxidized low-density lipoprotein based on immunoturbidimetry, and the method comprises the following steps: preparing a macroinitiator by active esterification reaction, and preparing a block graft copolymer by atom transfer radical polymerization and radical grafting reaction; the preparation method comprises the following steps: carrying out surface modification on latex microspheres with different particle sizes by using a grafted copolymer, and then respectively coupling the microspheres with different particle sizes with different OxLDL monoclonal antibodies so as to prepare a double-particle-size latex microsphere marker; and mixing the serum sample with the double-particle-size latex microsphere marker, measuring an absorbance value, and calculating the concentration of the oxidized low-density lipoprotein in the serum sample according to a standard curve established on the basis of the standard substance solution. According to the scheme, the stability of the latex microsphere marker can be enhanced, and the binding efficiency of the latex microsphere marker and ox-LDL can be improved.
Owner:XIAN GOLDMAG NANOBIOTECH +1

Construction method and application of blood sinus networked liver organoid

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.
Owner:QIJIA TECH (SUZHOU) CO LTD

Application of Sdccag3 gene in preparation of weight-reducing medicine for regulating glucose and lipid metabolism

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.
Owner:SHANDONG UNIV

Mycoplasma hyopneumoniae multi-antigen fusion protein and vaccine composition and application thereof

The invention discloses a mycoplasma hyopneumoniae multi-antigen fusion protein and a vaccine composition and application thereof, and belongs to the technical field of genetic engineering and vaccines. The fusion protein comprises an escherichia coli heat-labile enterotoxin LTB, a mycoplasma hyopneumoniae antigen protein P97R1, a mycoplasma hyopneumoniae lipoprotein 418 and a mycoplasma hyopneumoniae surface antigen protein P46 from the N terminal to the C terminal in the sequence. The vaccine composition comprises the fusion protein and an adjuvant acceptable in veterinary medicine. A vaccine prepared from the fusion protein has the advantages of higher pertinence and immunogenicity, the cell and humoral immune response level is remarkably improved, and meanwhile, the fusion protein is easy to purify and prepare and suitable for large-scale industrial production.
Owner:INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI

A lipoprotein subtype detection kit, its preparation method and application

The present invention provides a lipoprotein subtype detection kit, a preparation method and an application thereof, belonging to the technical field of biological detection. In the separating gel of the kit, BODIPY 505 / 515 is mixed, so that staining is not required during detection, and direct sample loading and electrophoresis can be carried out, reducing the operation steps and shortening the operation time, and improving the detection sensitivity. In addition, N,N'-bisacryloylpiperazine is mixed in both the separating gel and the stacking gel. The rigidity of the N,N'-bisacryloylpiperazine gel is used to reduce gel deformation and trailing phenomena during migration, significantly improving the resolution, and enhancing the stability and repeatability of detection. The detection kit provided by the present invention has the advantages of short detection operation time, high detection sensitivity, high resolution, good stability and repeatability.
Owner:FOSHAN KAISHI INTELLIGENT TECH CO LTD +1

Enterococcus faecalis EF-1 capable of reducing blood lipid, microbial preparation and application of enterococcus faecalis EF-1

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.
Owner:FEED RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Site-directed editing of RNA

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.
Owner:AIRNA CORPORATION +5

Lipoprotein sample separation method based on instant staining

The invention relates to the technical field of biological detection, and discloses an instant staining lipoprotein sample separation method, which comprises the following steps: S1, lipoprotein staining: taking 10 [mu] L of a sample loading staining solution, adding 50 [mu] L of a plasma lipoprotein sample, and completing staining without waiting and heating incubation; s2, sample loading of dyed lipoprotein: assembling a sample density separation liquid pre-loading column in a disc electrophoresis tank, adding an electrophoresis buffer solution, and adding the lipoprotein sample dyed in the step S1 to the upper end of the sample density separation liquid pre-loading column; and S3, electrophoretic separation of the lipoprotein subtypes: switching on a power supply of an electrophoresis apparatus, enabling the lipoprotein with negative charges to migrate to a positive electrode under the action of an electric field, and realizing separation according to different particle sizes of the lipoprotein subtypes. The lipoprotein loading staining solution is good in dispersity and uniformity, and in the preparation process of the lipoprotein loading staining solution, the dye does not need to be filtered to remove insoluble substances and does not need to be heated; the staining solution is good in stability and can be stored at normal temperature.
Owner:ANHUI HAOTUO BIOTECHNOLOGY CO LTD

4-(pyridine-4-yl)-1H-imidazole-2-amine derivatives and compositions targeting Gram-negative bacterium outer membrane assembly key protein machines

The invention discloses 4-(pyridine-4-yl)-1H-imidazole-2-amine derivatives and compositions of a machine for assembling key proteins on an outer membrane of targeted gram-negative bacteria, and belongs to the technical field of chemical medicines. The invention provides a small molecule compound as shown in a formula (I): # imgabs0 #, the small molecule compound can be used as a brand new targeting gram-negative bacterium inner membrane lipoprotein positioning machine (LolCDE) and has bacteriostatic activity, and a new way is provided for specific antibacterial treatment of gram-negative bacteria.
Owner:SICHUAN UNIV

Preparation method of oxidized low-density lipoprotein quality control product prepared based on novel antigen

The invention discloses a preparation method of an oxidized low-density lipoprotein quality control product prepared on the basis of a novel antigen, and the method comprises the following steps: constructing an oxidized low-density lipoprotein model, carrying out molecular dynamics simulation by setting a plurality of groups of simulation conditions to calculate a stability index, and determining an optimal antigen preparation condition; acquiring antigen epitope data, and constructing a feature vector, so as to predict and screen an optimal antigen epitope by utilizing a machine learning algorithm; and based on a target cross-linking strategy, combining the oxidized low-density lipoprotein prepared under the optimal antigen preparation condition with the optimal epitope to obtain a target quality control product. According to the scheme, the preparation efficiency and quality can be improved.
Owner:XIAN GOLDMAG NANOBIOTECH

Method and system for quantitatively detecting oxidized low-density lipoprotein based on magnetics

ActiveCN119044514AEfficient enrichmentAccurately capture and analyze color intensity changesColor/spectral properties measurementsBiological testingAntigenOxidised low density lipoprotein
The invention discloses a method and system for quantitatively detecting oxidized low-density lipoprotein based on magnetis.The method comprises the steps that a magnetic immune probe is prepared, and coupling efficiency is calculated by converting magnetic signal excitation energy into an electric signal; an immunochromatography test strip comprising a detection area, a quality control area and a binding area is constructed, and the detection of the concentration of the oxidized low-density lipoprotein is realized in combination with the establishment of a standard curve; a to-be-detected sample is applied to the sample pad of the test strip, the to-be-detected sample is combined with the magnetic particles marked with the oxidized low-density lipoprotein antibody through the position of the combination pad and flows to the part marked with another antibody on the nitrocellulose membrane, and a magnetic particle enrichment area is formed through specific recognition under the combination action of an antigen and an antibody; the oxidized low-density lipoprotein is quantitatively detected through magnetic signal acquisition and data processing. By means of the scheme, high sensitivity, high specificity and rapid detection of Ox-LDL can be achieved.
Owner:XIAN GOLDMAG NANOBIOTECH

Lactobacillus paracasei Jlus660321 with function of assisting in reducing blood fat and cholesterol and application of lactobacillus paracasei Jlus660321

The invention belongs to the field of microorganisms, and provides lactobacillus paracasei Jlus660321 with a function of assisting in reducing blood fat and cholesterol and application of the lactobacillus paracasei Jlus660321, and the preservation number of the lactobacillus paracasei Jlus660321 is CGMCC No. 33962. The lactobacillus paracasei Jlus 660321 has the functions of assisting in lowering blood fat and lowering cholesterol, shows excellent cholesterol lowering performance in a cholesterol degradation experiment, and can degrade 61.60% of cholesterol in the experiment. A hemolysis experiment result is gamma-hemolysis, namely, hemolysis is avoided, and toxic and side effects are small. Rat in-vivo experiments show that the lactobacillus paracasei Jlus 660321 can effectively slow down the increase of body weight, liver weight, liver index, low-density lipoprotein content and triglyceride content caused by high-fat diet, and further show that the lactobacillus paracasei Jlus 660321 has the function of assisting in reducing blood fat and cholesterol; the compound can be used for preparing medicines, nourishment or health care products for assisting in reducing blood fat and / or reducing cholesterol.
Owner:JILIN UNIVERSITY +1

Strain of bifidobacterium longum subsp. longum and use thereof in preventing, alleviating, regulating, or treating lipid metabolism-related diseases

PCT designated stageWO2025246510A1BacteriaMetabolism disorderDiseaseLow insulin
Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.
Owner:DIPROBIO (SHANGHAI) CO LTD

Lactobacillus plantarum YBE2 and application thereof

The invention discloses lactobacillus plantarum YBE2 and application thereof.According to the lactobacillus plantarum YBE2 for high yield of extracellular polysaccharide mainly containing rhamnose, different cholate types can be degraded at the same time, glycocholic acid is specifically hydrolyzed, and the lactobacillus plantarum YBE2 has the effects of lowering cholesterol and relieving acute inflammation at the same time. Meanwhile, the plant lactobacillus YBE2 can reduce the deposition of fat in the belly of the cage rearing broiler chicken, improve intramuscular fat, promote the deposition of fatty acid in muscles, reduce the total bile acid of plasma, triglyceride and low-density lipoprotein cholesterol, and remarkably improve the lipid metabolism and muscle quality of meat poultry, and can be widely applied to the breeding of the cage rearing broiler chicken, promote the healthy breeding of the meat poultry and improve the quality of the meat poultry. The culture benefit is improved.
Owner:NANJING NORMAL UNIVERSITY +1

Lipoprotein subtype detection kit as well as preparation method and application thereof

The invention provides a lipoprotein subtype detection kit as well as a preparation method and application thereof, and belongs to the technical field of biological detection.The separation gel of the kit is mixed with BODIPY 505 / 515, so that dyeing is not needed during detection, direct sample loading electrophoresis can be realized, the operation step flow is reduced, the operation time is shortened, and the detection sensitivity is improved; besides, the N, N-bisacryloyl piperazine is mixed in the separation gel and the concentrated gel, the gel deformation and trailing phenomena in the migration process are reduced by utilizing the rigidity of the N, N-bisacryloyl piperazine gel, the resolution ratio is remarkably improved, and the detection stability and repeatability can be improved; the detection kit provided by the invention has the advantages of short detection operation time, high detection sensitivity, high resolution and good stability and repeatability.
Owner:FOSHAN KAISHI INTELLIGENT TECH CO LTD +1

Polynucleic acid molecules for inhibiting expression of LP(a) or APOC3, pharmaceutical compositions, and uses thereof

PCT designated stageWO2025170868A1Organic active ingredientsMetabolism disorderA lipoproteinApolipoprotein C3
Disclosed herein are polynucleic acid molecules that can be utilized for suppressing the expression of lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3). Also, described herein are pharmaceutical compositions comprising polynucleic acid molecules targeting lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3) mRNA. Further provided herein are methods for suppressing the expression of lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3) by utilizing the polynucleic acid molecules described herein.
Owner:SIRIUS THERAPEUTICS INC

New application and method of asiaticoside

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.
Owner:HAINAN HAIZHIGE INVESTMENT CO LTD

Triglyceride determination kit

The invention provides a triglyceride determination kit, the kit comprises a reagent 1 and a reagent 2, the reagent 1 comprises the following main components: piperazine-1, 4-diethyl sulfonic acid (PIPES) buffer solution (pH 6.8), glycerophosphate oxidase (GPO), peroxidase (POD), triadenosine phosphate (ATP), chromogen, a surfactant, a stabilizer and a preservative; and the reagent 2 comprises the following main components: a piperazine-1, 4-diethyl sulfonic acid (PIPES) buffer solution (pH is 6.5), lipoprotein esterase (LPL), glycerol kinase (GK), 4-aminoantipyrine (4-AA), a surfactant, a stabilizer and a preservative. By optimizing a chromogen substrate in the reagent and adding potassium ferrocyanide, the linear range of the prepared kit is wider, and the bottle opening test is more stable.
Owner:JIANGSU MAIYUAN BIOTECHNOLOGY CO LTD

RNAi agents targeting LPA genes and uses thereof

Provided are an RNAi agent targeting a lipoprotein (a) (LPA) gene and a use thereof, and more particularly, an RNAi agent comprising an antisense strand having sequence complementarity with an LPA mRNA sequence and a sense strand having sequence complementarity with the antisense strand, and a pharmaceutical composition for preventing or treating cardiovascular diseases comprising the RNAi agent.
Owner:HANSOH (SHANGHAI) HEALTHTECH CO LTD +1

Utility of protein in the prediction of in vivo effects

A method of evaluating disposition and / or effect of a candidate compound in an in vitro culture and / or suspension to predict in vivo disposition and / or effect of the candidate compound, which can include the steps of providing a cell culture and / or suspension; exposing a candidate compound to the culture and / or suspension; exposing the culture and / or suspension to a media providing an in vivo relevant extracellular environment, such as a media comprising a component (such as a protein and / or other component, such as lipoproteins, bile acids, and endogenous compounds such as bilirubin) at a physiologic concentration or a concentration having characteristics, such as binding characteristics, similar to the physiological concentration; wherein any combination of any of the exposing steps can occur in any order or simultaneously; and evaluating in vitro disposition and / or effect of the compound to predict in vivo disposition and / or effect of the candidate compound.
Owner:QUALYST TRANSPORTER SOLUTIONS LLC

4-(1H-pyrazol-4-yl) pyridine derivative targeting Gram-negative bacteria lipoprotein transport pathway, composition and application of 4-(1H-pyrazol-4-yl) pyridine derivative

The invention discloses 4-(1H-pyrazol-4-yl) pyridine derivatives targeting a gram-negative bacteria lipoprotein transport pathway, a composition and application of the 4-(1H-pyrazol-4-yl) pyridine derivatives and belongs to the technical field of chemical medicines. The invention provides 4-(1H-pyrazol-4-yl)-2, 6-dimethyl pyridine and 4-(1H-pyrazol-4-yl) pyridine derivatives with the following structures: # imgabs0 #, the compounds can target a key protein machine of Gram's inner and outer membranes, and have remarkable antibacterial activity; meanwhile, the polypeptide can target key protein machines of gram inner and outer membranes, has good affinity with target protein LolCDE, and provides a new way for specific antibacterial treatment of gram-negative bacteria.
Owner:SICHUAN UNIV